Ponatinib Improves ⁣MRD Negativity in Philadelphia Chromosome-Positive ALL

Updated June 01, 2025

According to findings​ from the PhALLCON study, ponatinib demonstrates a greater rate of ‌minimal residual disease (MRD) negativity‍ compared to imatinib in patients with Philadelphia‍ chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Dr. Ibrahim Aldoss, associate professor at‌ City of Hope, presented these results at⁢ the American Society of Clinical Oncology (ASCO) meeting, noting the‌ correlation between MRD negativity and improved long-term survival.

While long-term event-free survival data ⁣from PhALLCON is still pending,preliminary ​results indicate improved progression-free survival with ponatinib. A post hoc analysis revealed that⁢ patients who continued ⁢receiving ponatinib after not achieving MRD negativity at three months experienced better event-free survival compared to⁤ those on imatinib.

The PhALLCON study also provided insights into using MRD as an endpoint. Patients achieving MRD negativity generally experienced favorable outcomes ⁣regarding long-term survival and event-free‍ survival.Further follow-up is anticipated to provide more clarity on the ⁤benefits of early MRD negativity.

Regarding the side effect profile, no important differences in treatment-emergent adverse events ⁤were⁢ observed between the ponatinib and imatinib cohorts, even with extended therapy duration. Arterial occlusive events were⁢ rare and comparable in both arms, potentially attributed to the reduced ponatinib dose (30 ‌mg initially, then 15 mg‌ upon complete molecular remission) and the‍ exclusion of patients with severe cardiovascular comorbidities from the study.

What’s‍ next

Researchers await mature data from the PhALLCON study to confirm if ponatinib is definitively ‍associated with improved event-free survival compared to ⁣imatinib in‍ the long term. Continued monitoring of patients will provide further insights into the sustained benefits of ponatinib in treating Ph+ ⁢ALL.